Our groups have common interests in the development of improved techniques for generating pluripotent stem cells, directing their differentiation into relevant tissues, and in disease modeling in two major systems of central interest to the NHLBI-the cardiovascular system and the blood. While the causative genetic lesion has been identified for many conditions, certain inborn and acquired hematologic disorders continue to cause significant morbidity and mortality. The limitations of animal and in vitro models is particularly relevant to the hematopoietic system, where engineering gene defects into mouse strains has failed to phenocopy cardinal features of diseases like Fanconi anemia and Down Syndrome. Human models would offer a relevant system to study these diseases and to develop therapeutics. We have pioneered methods for somatic cell reprogramming to generate mouse and human induced pluripotent stem cells (IPS) and bring considerable experience to the directed differentiation of embryonic stem (ES)/ IPS cells into hematopoietic lineages. We wish to exploit these new "humanized" research tools to complement our traditional expertise in zebrafish and murine models to study hematopoietic development and disease pathophysiology. In this proposal we plan to create and study human IPS cells for genetic blood diseases that: disrupt genomic stability (Fanconi's anemia and Dyskeratosis congenita), specify aberrant nucleolar or ribosomal proteins (Shwachman-Bodian-Diamond Syndrome and Diamond-Blackfan Anemia), and represent a constitutional'trisomy with prominent hematologic and cardiac anomalies (Down Syndrome). With these IPS cells, we will explore disease phenotypes, pursue strategies for gene repair, and search for novel therapeutics that might ameliorate these conditions. This proposal is part of a collaborative R03 application with Drs Ken Chien and Kit Parker, cardiovascular researchers at the Massachusetts General Hospital, and Doug Melton, a stem cell researcher at Harvard University, and has three specific aims:
Aim #1 : Generate human induced pluripotent stem cells from patients with genetic and acquired disorders of the hematopoietic system.
Aim #2 : Explore the hematopoietic phenotypes of disease-specific IPS cells.
Aim #3 : Investigate methods for gene repair, and pursue chemical and genetic screening to identify novel small molecules and genetic pathways to ameliorate the disease phenotypes in vitro.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-J (S1))
Program Officer
Thomas, John
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Hospital Boston
United States
Zip Code
Arora, Natasha; Wenzel, Pamela L; McKinney-Freeman, Shannon L et al. (2014) Effect of developmental stage of HSC and recipient on transplant outcomes. Dev Cell 29:621-8
Morris, Samantha A; Cahan, Patrick; Li, Hu et al. (2014) Dissecting engineered cell types and enhancing cell fate conversion via CellNet. Cell 158:889-902
Hagedorn, Elliott J; Durand, Ellen M; Fast, Eva M et al. (2014) Getting more for your marrow: boosting hematopoietic stem cell numbers with PGE2. Exp Cell Res 329:220-6
Cahan, Patrick; Li, Hu; Morris, Samantha A et al. (2014) CellNet: network biology applied to stem cell engineering. Cell 158:903-15
Das, Partha Pratim; Shao, Zhen; Beyaz, Semir et al. (2014) Distinct and combinatorial functions of Jmjd2b/Kdm4b and Jmjd2c/Kdm4c in mouse embryonic stem cell identity. Mol Cell 53:32-48
Guo, Guoji; Luc, Sidinh; Marco, Eugenio et al. (2013) Mapping cellular hierarchy by single-cell analysis of the cell surface repertoire. Cell Stem Cell 13:492-505
Kim, Peter Geon; Albacker, Colleen E; Lu, Yi-fen et al. (2013) Signaling axis involving Hedgehog, Notch, and Scl promotes the embryonic endothelial-to-hematopoietic transition. Proc Natl Acad Sci U S A 110:E141-50
Cherry, Anne B C; Daley, George Q (2013) Reprogrammed cells for disease modeling and regenerative medicine. Annu Rev Med 64:277-90
Cahan, Patrick; Daley, George Q (2013) Origins and implications of pluripotent stem cell variability and heterogeneity. Nat Rev Mol Cell Biol 14:357-68
Shyh-Chang, Ng; Daley, George Q (2013) Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell 12:395-406

Showing the most recent 10 out of 26 publications